LOS ANGELES--(BUSINESS WIRE)--Puma Biotechnology, Inc. (NASDAQ: PBYI), a biopharmaceutical company, announced that Alan H. Auerbach, Chairman, Chief Executive Officer, President and Founder of Puma, will present an overview of the Company at the hybrid H.C. Wainwright 24th Annual Global Investment Conference, which will be held September 12-14, 2022. The virtual presentation will be available for 30 days beginning at 7:00 a.m. EDT on September 12, 2022 on the Companys website at https://www.pumabiotechnology.com.

About Puma Biotechnology

Puma Biotechnology, Inc. is a biopharmaceutical company with a focus on the development and commercialization of innovative products to enhance cancer care. Puma in-licenses the global development and commercialization rights to PB272 (neratinib, oral), PB272 (neratinib, intravenous) and PB357. Neratinib, oral was approved by the U.S. Food and Drug Administration in 2017 for the extended adjuvant treatment of adult patients with early stage HER2-overexpressed/amplified breast cancer, following adjuvant trastuzumab-based therapy, and is marketed in the United States as NERLYNX (neratinib) tablets. In February 2020, NERLYNX was also approved by the FDA in combination with capecitabine for the treatment of adult patients with advanced or metastatic HER2-positive breast cancer who have received two or more prior anti-HER2-based regimens in the metastatic setting. NERLYNX was granted marketing authorization by the European Commission in 2018 for the extended adjuvant treatment of adult patients with early stage hormone receptor-positive HER2-overexpressed/amplified breast cancer and who are less than one year from completion of prior adjuvant trastuzumab-based therapy. NERLYNX is a registered trademark of Puma Biotechnology, Inc.

Further information about Puma Biotechnology may be found at https://www.pumabiotechnology.com.

See the rest here:
Puma Biotechnology to Present at the H.C. Wainwright 24th Annual Global Investment Conference - Business Wire

The biotech industry is heavily regulated by the federal government and its science watchdog, the Food and Drug Administration (FDA). As a consequence, biotech investors often evaluate a possible investment by looking at the company's pipeline of future assets. Research and development is a key factor in this sector.

So what biotech companies have the most exciting future prospects? Three Fool.com healthcare contributors like Vertex Pharmaceuticals (VRTX 1.88%), Repligen (RGEN 4.51%), and Recursion Pharmaceuticals (RXRX 9.43%). Here's why they believe these three stocks are the future of biotechnology.

George Budwell (Vertex Pharmaceuticals): Vertex Pharmaceuticals has become a cash-printing machine recently thanks to its groundbreaking cystic fibrosis treatments like Trikafta. This single drug generated a whopping $5.7 billion in sales in 2021.

The company has been using the proceeds from its mega-blockbuster cystic fibrosis franchise to expand into cutting-edge treatment modalities such as stem cell therapy and gene editing. For example, Vertex dipped into its cash reserves in the recent past to buy the privately held biotechs Semma Therapeutics and ViaCyte. These complementary transactions have suddenly made Vertex a potential juggernaut in the world of diabetes care.

The 2019 Semma Therapeutics deal gave the biotech the allogeneic stem-cell product VX-880, aimed at curing type 1 diabetes. And earlier this year, Vertex bought ViaCyte for its cell replacement therapy platform, which is also initially aimed at curing type 1 diabetes.

This ViaCyte transaction also stands out because the biotech has an ongoing collaboration with Vertex's blood disease collaborator, CRISPR Therapeutics. This ViaCyte/CRISPR partnership centers around the development of genetically modified beta cells for the treatment of both type 1 and type 2 diabetes. CRISPR and ViaCyte are reportedly on track to release top-line data from an early-stage trial in type 1 diabetes next year. Human trials for the duo's type 2 therapy could kick off in either late 2023 or early 2024.

In sum, Vertex's cell- and gene-editing-based diabetes care therapies have the potential to bend the curve in terms of the standard of care for this worldwide epidemic. Wall Street, however, doesn't appear to have taken notice of this deep value proposition -- at least not yet. Vertex's stock, after all, seems to be being valued mainly for its cystic fibrosis franchise and pipeline assets in various blood disorders.

Patrick Bafuma (Repligen): When it comes to the future, Repligen is creating the tools that make it all possible. From cell and gene therapy to cutting-edge mRNA vaccines to monoclonal antibody treatment, Repligen is there. This biotech provides the equipment and associated consumables needed for various steps in the manufacturing of today's most complex treatments.

And in a year marred by supply chain and geopolitical issues, Repligen has seemingly been insulated. There was hardly a mention of either of these issues in the last few earnings conference calls. Not bad considering its sales are spread throughout the globe with Europe, North America, and Asia representing 35%, 45%, and 20% of second-quarter revenue, respectively. Despite sales slowing down for COVID-19 treatments and vaccines that Repligen helps manufacture, the company's base business in Q2 was up 41% year over year. The record quarterly revenue of $207.6 million -- up 32% year over year on a constant currency basis -- is a welcome sight for biotech investors in 2022's uncertain market.

If you believe cell and gene therapy are the future of healthcare, then Repligen deserves a second look. The bioprocessing company's cell and gene therapy segment is seeing accelerated growth. Revenue from this business line increased 40% in full year 2021, and growth in Q2 2022 was up almost 70% from the same period a year ago. This puts Repligen on track to smash its own 40% growth target for the division for 2022. There are other signs the future is bright, too. At the end of 2020, there were over 1,200 clinical trials underway worldwide in the cell and gene therapy segment, according to the company. Then there are the FDA estimates for annual revenue growth of over 25% for the entirety of said market through 2025. Put it all together, and Repligen is well positioned to thrive as the backbone of the industry.

Taylor Carmichael (Recursion Pharmaceuticals): Vertex and Repligen are great picks. Both companies are already highly profitable, so the future prospects are grounded in what these companies have already accomplished. Recursion is a different animal. The company doesn't have profits yet, and revenue is still small. But I've opened up a small position here because the upside is so high. If this company has any success, it will dramatically transform drug discovery.

Here's the current paradigm for finding a new drug candidate. You notice a problem in the world of healthcare. You read academic articles to see what has been tried and what has not been tried. You formulate your own hypothesis. And then you collect data by testing your hypothesis in animals, and then in people. That's the basic model for drug discovery -- and it has a spectacular failure rate of over 90%.

Recursion is using supercomputers and artificial intelligence (AI) to create maps of biology. The company's software has already generated 16 petabytes of biological and chemical data. One petabyte equals 1.5 million CD-ROM discs. It's estimated the human brain can store 2.5 petabytes of memory data. So Recursion's AI solution now has more data than six human brains.

Even more importantly, the company's AI solution is running experiments with this data all the time. Recursion's computers have now made 2.4 trillion predictions about biological and chemical relationships. Research scientists can search all this data to create a more informed hypothesis. This is a fundamentally superior model, in my opinion. First you collect and analyze the scientific data, and then you form the hypothesis.

The company has major partners inBayerand Roche. And Recursion has quickly found drug candidates. In the first quarter, the company initiated a phase 2 study for a drug to treat cerebral cavernous malformation. In Q2, the company started a phase 2 study for a molecule to treat neurofibromatosis type 2. This quarter the company will initiate yet another phase 2 study, in a drug treating familial adenomatous polyposis (FAP).

Of course improving the odds does not mean that these drugs are sure things. But I definitely think Recursion is on the right track, and the future of drug discovery will follow this model. So I've made a small investment here while it's early and the company is still small. (Its market cap is under $2 billion.) If I'm right, Recursion will be a foundational holding for biotech investors for many years to come.

Read this article:
These 3 Stocks Are the Future of Biotechnology - The Motley Fool

DUBLIN, Ireland, Sept. 01, 2022 (GLOBE NEWSWIRE) -- Prothena Corporation plc (NASDAQ:PRTA), a late-stage clinical biotechnology company with a robust pipeline of investigational therapeutics built on protein dysregulation expertise, announced today the appointment of Helen S. Kim, MBA, to its Board of Directors. Ms. Kim has over 27 years of experience in leadership roles in biotechnology, including her previous role as Executive Vice President of Business Development at Kite Pharma, Inc. where she led all business and corporate development initiatives, leading to a successful acquisition by Gilead in 2017. With the appointment of Ms. Kim, Prothena will expand its Board to 10 directors.

Ms. Kims background and expertise in leadership roles across biotechnology companies for nearly three decades will be a welcome addition to the Board and will help guide Prothenas robust portfolio as the company moves towards commercialization, commented Lars G. Ekman, M.D., Ph.D., Prothenas Chairman. We welcome Ms. Kim to our Board and look forward to her many contributions.

After watching the strong execution of Prothena over the past years, Im excited to join the Board of Directors at this pivotal stage for the company. Their expertise in pioneering drugs targeting protein dysregulation is clearly reflected in the robust and promising pipeline of novel programs in areas of high unmet need, said Ms. Kim. I look forward to working with the other board members and the leadership team to continue Prothenas progress in advancing novel medicines for neurodegenerative and rare peripheral amyloid diseases, which affect millions of people and their families worldwide.

Currently, Ms. Kim serves as a Senior Managing Director at Vida Ventures, LLC (a venture capital firm), a position which she has held since April 2019. Prior to her current role, Ms. Kim was a Partner at the Column Group (a venture capital firm) from 2018-2019 and the Executive Vice President, Business Development at Kite Pharma, Inc. from 2014-2018. Previously, Ms. Kim held positions as Chief Business Officer (2009-2012) and then Strategic Advisor (2012-2014) of NGM Biopharmaceuticals, Inc. Prior to NGM, she was the Chief Executive Officer and President of Kosan Biosciences (a pharmaceutical company) where she restructured and repositioned the company prior to a successful transaction with Bristol Myers Squibb in 2008. Ms. Kims additional industry experience includes executive and leadership positions at Affymax, Inc., Onyx Pharmaceuticals, Inc., Protein Design Labs, Inc. (a technology company), and Chiron Corporation.

Ms. Kim currently serves on the Board of Directors for A2 Biotherapeutics, Inc., ReCode Therapeutics, Inc., IconOVir Bio, Inc., Aktis Oncology, PACT Pharma, Protego Therapeutics, and InduPro Labs. Ms. Kim received a B.S. in Chemical Engineering from Northwestern University and an MBA from the University of Chicago.

About ProthenaProthena Corporation plc is a late-stage clinical biotechnology company with expertise in protein dysregulation and a pipeline of investigational therapeutics with the potential to change the course of devastating neurodegenerative and rare peripheral amyloid diseases. Fueled by its deep scientific expertise built over decades of research, Prothena is advancing a pipeline of therapeutic candidates for a number of indications and novel targets for which its ability to integrate scientific insights around neurological dysfunction and the biology of misfolded proteins can be leveraged. Prothenas pipeline includes both wholly-owned and partnered programs being developed for the potential treatment of diseases including AL amyloidosis, ATTR amyloidosis, Alzheimers disease, Parkinsons disease and a number of other neurodegenerative diseases. For more information, please visit the Companys website at http://www.prothena.com and follow the Company on Twitter @ProthenaCorp.

Media and Investor Contact:

MediaMichael Bachner, Senior Director, Corporate Communications609-664-7308, michael.bachner@prothena.com

InvestorsJennifer Zibuda, Director, Investor Relations & Communications650-837-8535, jennifer.zibuda@prothena.com

A photo accompanying this announcement is available at https://www.globenewswire.com/NewsRoom/AttachmentNg/f753c7c6-4b3d-4059-ad0a-8515de183e27

Go here to see the original:
Prothena Announces Appointment of Biotechnology Industry Leader Helen S. Kim to its Board of Directors - GlobeNewswire

Sana Biotechnology Inc. (NASDAQ: SANA) stock fell -4.59% on Friday to $6.23 against a previous-day closing price of $6.53. With 1.08 million shares changed hands, the volume of the stock remained lighter than its average volume of 1.48 million shares. During the session, the Biotechnology company that operates in wider Healthcare sector, reached to the highest price of $6.63 whereas the lowest price it dropped to was $6.13. The 52-week range on SANA shows that it touched its highest point at $26.60 and its lowest point at $3.92 during that stretch. It currently has a 1-year price target of $13.33.

Lithium Stocks In The Spotlight

Here's a company undiscovered by Wall Street and trading below $0.30 per share which just recently uncovered 8 high-quality targets on unexplored ground, and drills will be turning later this year. Very few investors know about it yet so the ground-floor opportunity below $0.30 won't be around much longer. It's a brand new breed of lithium explorer all you need to do is click and the name and trading symbol is yours.

It's all in the FREE report you can get here..

Sponsored

Stock performance is one of the indicators that investors use to determine whether they will profit from a stock. The price performance of SANA was down-trending over the past week, with a drop of -3.26%, but this was down by -24.30% over a month. Three-month performance surged to 25.86% while six-month performance rose 18.89%. The stock lost -74.82% in the past year, while it has lost -59.75% so far this year. A look at the trailing 12-month EPS for SANA yields -1.61 with Next year EPS estimates of -2.37. For the next quarter, that number is -0.53. This implies an EPS growth rate of -37.80% for this year and -12.40% for next year.

At present, 187.63 million SANA shares are outstanding with a float of 168.88 million shares on hand for trading. On Jul 14, 2022, short shares totaled 22.35 million, which was 11.78% higher than short shares on Jun 14, 2022. In addition to Dr. Steven D. Harr M.D. as the firms Pres, CEO & Director, Dr. Richard C. Mulligan Ph.D. serves as its Exec. Vice Chairman & Head of SanaX.

Through their ownership of 85.43% of SANAs outstanding shares, institutional investors have majority control over the company. Other institutions hold 32.91% of SANA, in contrast to 26.79% held by mutual funds. Shares owned by individuals account for 15.06%. As the largest shareholder in SANA with 5.79% of the stake, Baillie Gifford & Co. holds 11,011,462 shares worth 11,011,462. A second-largest stockholder of SANA, Canada Pension Plan Investment Bo, holds 10,175,000 shares, controlling over 5.35% of the firms shares. SSgA Funds Management, Inc. is the third largest shareholder in SANA, holding 8,594,413 shares or 4.52% stake. With a 4.51% stake in SANA, the Canada Pension Plan is the largest stakeholder. A total of 8,581,595 shares are owned by the mutual fund manager. The SPDR S&P Biotech ETF, which owns about 3.67% of SANA stock, is the second-largest Mutual Fund holder. It holds 6,969,103 shares valued at 46.55 million. Scottish Mortgage Investment Trus holds 2.95% of the stake in SANA, owning 5,586,264 shares worth 37.32 million.

Reading analyst opinions is an effective way to decide where to invest, and there are several opinions available for SANA since 4 analysts follow the stock currently. There are 2 analysts who recommend BUY ratings, while 0 suggest SELL ratings. Of the remaining analysts, 2 believe that the stock is worth HOLDING, 0 give it an OVERWEIGHT rating, and 0 thinks that its UNDERWEIGHT. In the same way, a target price assigned to a stock can also reveal much about its potential. With SANA analysts setting a high price target of $18.00 and a low target of $7.00, the average target price over the next 12 months is $12.75. Based on these targets, SANA could surge 188.92% to reach the target high and rise by 12.36% to reach the target low. Reaching the average price target will result in a growth of 104.65% from current levels.

It is also common to use earnings estimates to evaluate a firms growth potential and to determine trading strategy. SANA will report FY 2022 earnings on 03/22/2023. Analysts have provided yearly estimates in a range of -$1.64 being high and -$2.30 being low. For SANA, this leads to a yearly average estimate of -$1.94. The earnings surprise of a firm occurs when the actual results change from the consensus earnings estimate. Sana Biotechnology Inc. surprised analysts by $0.04 when it reported -$0.47 EPS against a consensus estimate of -$0.51. The surprise factor in the prior quarter was $0.30. Based on analyst estimates, the high estimate for the next quarter is -$0.39 and the low estimate is -$0.53. The average estimate for the next quarter is thus -$0.48.

Insiders traded SANA stock several times over the past three months with 3 Buys and 0 Sells. In these transactions, 70,390 shares were bought while 0 shares were sold. The number of buy transactions has increased to 9 while that of sell transactions has risen to 6 over the past year. The total number of shares bought during that period was 142,888 while 126,481 shares were sold.

Read more here:
Stocks of Sana Biotechnology Inc. (SANA) are poised to climb above their peers - SETE News

PARIS & CAMBRIDGE, Mass. & SHANGHAI, China & PRINCETON, N.J.--(BUSINESS WIRE)-- Regulatory News:

NANOBIOTIX (Euronext: NANO Nasdaq: NBTX), a late-stage clinical biotechnology company pioneering physics-based approaches to expand treatment possibilities for patients with cancer, and LianBio (Nasdaq: LIAN), a biotechnology company dedicated to bringing paradigm-shifting medicines to patients in China and major Asian markets today announced randomization of the first patient in Asia in NANORAY-312, a global Phase 3 registrational trial evaluating NBTXR3 for the treatment of elderly patients with locally advanced head and neck squamous cell carcinoma (LA-HNSCC) who are ineligible for platinum-based chemotherapy.

We believe NBTXR3 has demonstrated the potential to improve treatment outcomes in multiple solid tumor indications, including in Study 102, the Nanobiotix Phase 1 trial evaluating the product candidate for the treatment of elderly patients with locally advanced head and neck squamous cell carcinoma, said Yizhe Wang, Ph.D., Chief Executive Officer, LianBio. We look forward to working with our clinical partners at sites across Greater China and South Korea to evaluate NBTXR3 in this difficult-to-treat patient population. With radiotherapy usage on the rise in Asia, we believe NBTXR3 may become an important part of the treatment landscape for patients with cancer in the region.

NANORAY-312 is a global, two-arm, randomized, Investigators Choice Phase 3 registrational study that is designed to investigate the efficacy and safety of radiotherapy-activated NBTXR3 with or without cetuximab versus radiotherapy with or without cetuximab in high-risk, chemotherapy-ineligible elderly patients with LA-HNSCC. Eligible participants for NANORAY-312 will be treated with NBTXR3 at a 1:1 ratio after an Investigators Choice of radiotherapy alone or radiotherapy in combination with cetuximab. This pivotal trial is expected to enroll 500 patients globally, with approximately 100 patients expected to be enrolled in LianBios licensed territories participating in the study.

NANORAY-312 builds on Nanobiotix Study 102, a Phase 1 trial evaluating safety and early signs of efficacy for radiotherapy-activated NBTXR3 in high-risk elderly LA-HNSCC patients who are chemotherapy-ineligible and intolerant to cetuximab. To date, Study 102 has demonstrated median overall survival of 17.9 months in the all-treated population (n=56) and 23.0 months in the evaluable patients (n=44).

LianBio holds exclusive rights to develop and commercialize NBTXR3 in Greater China, South Korea, Singapore and Thailand.

***

About NBTXR3

NBTXR3 is a novel, potentially first-in-class oncology product composed of functionalized hafnium oxide nanoparticles administered via one-time intratumoral injection and activated by radiotherapy. The product candidates physical mechanism of action (MoA) is designed to induce significant tumor cell death in the injected tumor when activated by radiotherapy, subsequently triggering adaptive immune response and long-term anti-cancer memory. Given the physical MoA, Nanobiotix believes that NBTXR3 could be scalable across solid tumors that can be treated with radiotherapy and across different therapeutic combinations. The U.S. Food and Drug Administration (FDA) has granted Fast Track designation for the investigation of radiotherapy-activated NBTXR3 in the NANORAY-312 population.

About NANOBIOTIX

Nanobiotix is a late-stage clinical biotechnology company pioneering disruptive, physics-based therapeutic approaches to revolutionize treatment outcomes for millions of patients; supported by people committed to making a difference for humanity. Nanobiotix is leveraging its proprietary nanoparticle platform, including its lead product candidate, radiotherapy activated NBTXR3, to develop a pipeline of therapeutic options designed to enhance local and systemic control of solid tumors with an initial focus on the treatment of head and neck cancers.

For more information about Nanobiotix, visit us at http://www.nanobiotix.com or follow us on LinkedIn and Twitter

About LianBio

LianBio is a cross-border biotechnology company on a mission to bring transformative medicines to patients in China and other Asian markets. Through partnerships with highly innovative biopharmaceutical companies around the world, LianBio is advancing a diversified portfolio of clinically validated product candidates with the potential to drive new standards of care across cardiovascular, oncology, ophthalmology, inflammatory disease and respiratory indications. LianBio is establishing an international infrastructure to position itself as a partner of choice with a platform to provide access to China and other Asian markets. For more information, please visit http://www.lianbio.com.

Disclaimer

This press release contains certain forward-looking statements within the meaning of applicable securities laws, including the Private Securities Litigation Reform Act of 1995. Forward-looking statements may be identified by words such as at this time, anticipate, believe, expect, intend, on track, plan, scheduled, and will, or the negative of these and similar expressions. These forward-looking statements, which are based on Nanobiotix and LianBios current expectations and assumptions and on information currently available to management, include statements about NBTXR3s potential as a clinical candidate, including: (i) its potential role as part of the treatment landscape for cancer patients; (ii) the timing and progress of clinical trials; (iii) the expected timing of Nanobiotix or LianBios presentation of data; (iv) the results of Nanobiotixs preclinical or clinical studies and their potential implications; (v) the potential for results from NANORAY-312 to support regulatory approval in LianBios licensed territories in Asia; and (vi) the development of NBTXR3 in Asian markets under Nanbiotixs license agreement with LianBio. Such forward-looking statements are made in light of information currently available to Nanobiotix and LianBio and are based on assumptions that Nanobiotix and LianBio consider to be reasonable. However, these forward-looking statements are subject to numerous risks and uncertainties, including: (i) with respect to the risk that subsequent studies and clinical trials may not generate favorable data notwithstanding positive preclinical results; and (ii) the risks associated with the evolving nature, duration, and severity of the COVID-19 pandemic along with governmental and regulatory measures implemented in response. Furthermore, many other important factors, including: (i) those described in Nanobiotixs Annual Report on Form 20-F filed with the U.S. Securities and Exchange Commission (the SEC) on April 8, 2022 under Item 3.D. Risk Factors; (ii) those set forth in the universal registration document of Nanobiotix filed with the French Financial Markets Authority (Autorit des marchs financiers) under number D.21-0272 on April 8, 2022 (a copy of which is available on http://www.nanobiotix.com); and (iii) in LianBios Annual Report on Form 10-K for the year ended December 31, 2021 and subsequent filings with the SEC, as well as other known and unknown risks and uncertainties, may adversely affect such forward-looking statements and cause actual results, performance, or achievements to be materially different from those expressed or implied by the forward-looking statements. Except as required by law, neither Nanobiotix nor LianBio assume any obligation to update these forward-looking statements publicly, or to update the reasons why actual results could differ materially from those anticipated in the forward-looking statements, even if new information becomes available in the future.

View source version on businesswire.com: https://www.businesswire.com/news/home/20220907006108/en/

Continue reading here:
NANOBIOTIX and LianBio Announce First Patient Enrolled in Asia in Phase 3 NANORAY-312 Trial Evaluating NBTXR3 for the Treatment of Head and Neck...

Marketreports.info has released a report titled Global Separation Systems For Commercial Biotechnology Market that includes industry growth factors for the projected period of 2022-2030. The information looks at a significant global Separation Systems For Commercial Biotechnology market, the dynamics driving it, the factors restraining it, and the opportunities for growing demand.

The full report appropriately depicts the geographic coverage of the global Separation Systems For Commercial Biotechnology market. This study provides a benchmark analysis based on corporate insights, distribution channels, market share, regional presence, business strategy, leveraged buyouts, technological advances, recent news, joint projects, agreements, SWOT analysis, and critical financial data.

DOWNLOAD FREE SAMPLE REPORT: marketreports.info/sample/90268/Separation-Systems-For-Commercial-Biotechnology

The regions and countries are discussed in the global Separation Systems For Commercial Biotechnology market report:

North America (United States, Canada and Mexico)

Europe (Germany, France, United Kingdom, Russia, Italy, and Rest of Europe)

Asia-Pacific (China, Japan, Korea, India, Southeast Asia, and Australia)

South America (Brazil, Argentina, Colombia, and Rest of South America)

Middle East & Africa (Saudi Arabia, UAE, Egypt, South Africa, and Rest of Middle East & Africa)

Segments covered in this report are:

By TypeType Type Type Type Type By ApplicationApplication Application Application Application Application

They are the key players profiled in the global market report:

Company 1, Company 2, Company 3, Company 4, Company 5, Company 6, Company 7, Company 8, Company 9, Company 10, Company 11, Company 12, Company 13, Company 14, Company 15

ACCESS FULL REPORT: marketreports.info/industry-report/90268/Separation-Systems-For-Commercial-Biotechnology

The study examines global Separation Systems For Commercial Biotechnology market trends, inflation rates, driving factors, and competition intensity by segment. The news gathers first-hand knowledge, descriptive and analytical assessments by industry analysts, and input from professionals in the field and content providers at all phases of the manufacturing process.

One of the most critical factors in collecting this report was its correctness and statistics research methodology. The data is combined with a diverse mix of experience, analytics, machine learning, and data science to produce research approaches that result in a various yet accurate analysis of the worldwide Separation Systems For Commercial Biotechnology market.

Important Questions Answered:

Which Separation Systems For Commercial Biotechnology market segments are attracting the most attention?

Who are the major market players contending with and developing in the Separation Systems For Commercial Biotechnology market?

Customization of the Separation Systems For Commercial Biotechnology Report:

This report can be customized to meet the clients requirements. Please connect with our sales team (sales@marketreports.info), who will ensure that you get a report that suits your needs. You can also get in touch with our executives directly to share your research requirements.

About Us

Marketreports.info is a global market research and consulting service provider specialized in offering wide range of business solutions to their clients including market research reports, primary and secondary research, demand forecasting services, focus group analysis and other services. We understand that how data is important in todays competitive environment and thus, we have collaborated with industrys leading research providers who works continuously to meet the ever-growing demand for market research reports throughout the year.

Contact Us:

CarlAllison (Head of Business Development)

Tiensestraat 32/0302,3000 Leuven, Belgium.

Market Reports

phone:+44 141 628 5998

Email: sales@marketreports.info

Website: http://www.marketreports.info

Read more here:
Separation Systems For Commercial Biotechnology Market increasing demand with Industry Professionals Fighting Hawks Magazine - Fighting Hawks...

SAN FRANCISCO BAY AREA, Calif., Sept. 7, 2022 /PRNewswire/ -- Rondo Therapeutics, a privately-held biotechnology company advancing next-generation immuno-oncology platforms, announces the addition of Carolyn Bertozzi, Ph.D., to its Scientific Advisory Board. Dr. Bertozzi is a Professor of Chemistry and Director of the Sarafan ChEM-H institute at Stanford Universityand is a world leader in the field of glycobiology, generating new insights regarding disease-associated changes in cell surface glycosylation patterns. Jessica Stark, Ph.D., an American Cancer Society postdoctoral fellow in the Bertozzi Research Group, is also joining Rondo as a scientific consultant. Dr. Stark has pioneered new approaches in understanding the role of glycobiology in the functioning of the innate immune system.

Dr. Bertozzi has been recognized with many honors and awards for both her research and teaching accomplishments. She is an elected member of the National Academy of Sciences, the American Academy of Arts and Sciences, and the German Academy of Sciences Leopoldina. Recent awards of note include the Welch Award in Chemistry (2022); The Dickson Prize in Medicine, University of Pittsburgh (2022); Dr H.P. Heineken Prize for Biochemistry and Biophysics (2022); Wolf Prize (2022); AAAS Lifetime Mentor Award (2022). Dr. Bertozzi is also an accomplished entrepreneur, having founded several biotech companies including Palleon Pharma and Lycia Therapeutics.

"We are excited and privileged to be working with both Carolyn and Jessica in an exciting new area of biology," said Nathan Trinklein, Ph.D., co-founder and President of Rondo Therapeutics. "By combining their deep biological knowledge with Rondo's unique ability to rapidly develop bispecific antibodies, we are aiming to create a new class of biologics with a unique mechanism of action."

"We are thrilled to be working with the Rondo team to take on glycobiology as an emerging frontier for immunotherapy," said Jessica Stark, Ph.D., American Cancer Society postdoctoral fellow at Stanford University. "Through development of a novel class of bispecifics, we hope to make a difference for patients in multiple solid tumor indications."

Dr. Bertozzi is joining a group of highly distinguished scientists and clinicians on Rondo's Scientific Advisory Board: James Ford, M.D., Professor of Medicine, Stanford University; Alessandra Cesano, CMO, ESSA Pharmaceuticals; and Leonard Presta, Ph.D., renowned Protein Engineer.

About Rondo Therapeutics

Rondo Therapeutics is a biopharmaceutical company exploring new frontiers in cancer therapy. Rondo is committed to advancing the field of immuno-oncology, with a focus on treating solid tumors that fail to respond to current therapies. Our solution is to create a new class of bispecific antibodies that safely engage the immune system to initiate and sustain a robust anti-tumor response and overcome the suppressive tumor microenvironment.

Learn more at: http://www.rondotx.com.

SOURCE Rondo Therapeutics

View post:
Carolyn Bertozzi, Professor and Director of the Sarafan ChEM-H institute at Stanford University, Joins the Rondo Therapeutics Scientific Advisory...

NANJING, China, Sept. 7, 2022 /PRNewswire/ -- InxMed Co., Ltd, a clinical-stage biotechnology company dedicates to developing innovative therapies targeting drug resistance and metastasis for hard-to-treat solid tumors, today announced the dosing of the first patient in its Phase 2 pivotal studyevaluating IN10018, a highly potent and selective oral inhibitor of focal adhesion kinase (FAK), in combination with pegylated liposomal doxorubicin (PLD) in patients with platinum-resistant recurrent ovarian cancer (PROC).

The Phase 2 pivotal study is a randomized, double-blind, placebo-controlled trial investigating the efficacy and safety of IN10018 in combination with PLD in patients with PROC. A total of 168 PROC patients will be enrolled and randomized in a 2: 1 ratio to receive IN10018 in combination with PLD or placebo of IN10018 in combination with PLD treatment in a double-blind manner.

Progression-free survival (PFS) as assessed by blinded independent central review (BICR) will be used as primary efficacy endpoint and overall survival (OS) will be used as key secondary efficacy endpoint. Objective remission rate (ORR), overall disease control rate (DCR), duration of remission (DOR), etc. as assessed by BICR and investigator will be other secondary efficacy endpoints.

InxMed previously reported results from its Phase Ib study of IN10018 in combination with PLD on ASCO 2022, demonstrated promising antitumor efficacy and a well-controlled safety profile in the treatment of patients with PROC.

The Phase 2 pivotal study was initiated inAugust 2022and is expected to be completed in Q1 2024. The company also has completed a Type B Meeting discussion with U.S. Food and Drug Administration (FDA) and planned to submit US IND for a Phase 2 pivotal studyevaluating IN10018 in combination with PLD for PROC in US by September this year.

InxMed set up a global clinical development program for IN10018. Clinical trials currently underway in the US, China and Australia are designed for platinum-resistant recurrent ovarian cancer, NRAS mutant metastatic melanoma, triple-negative breast cancer, head and neck cancer, pancreatic cancer, and other solid tumors that are still lacking effective treatment.IN10018 received fast track designation from the US FDA in August 2021, and breakthrough designation from China National Medical Products Administration(NMPA) in April 2022 for the treatment of patients with platinum-resistant ovarian cancer.

About InxMed

InxMed is a clinical-stage biotech company established in the end of 2018. The company dedicates on developing innovative therapies targeting stroma microenvironment and solid tumor resistance and metastasis, especially new drug development on anti PD-1/PD-L1 treatment drug resistance. InxMed committees to building an efficient engine for clinical translational science and proof of concept platform driven by in-depth understanding of disease biology and being a China based biotech company with global impact. We have built translational medicine and clinical development team across Shanghai, Beijing, Nanjing, United States, Canada and Australia. We have built a highly differentiated pipeline and established partnership with various multinational pharmaceutical companies including Merck, Roche and Boehringer Ingelheim.

SOURCE InxMed Co., Ltd

The rest is here:
InxMed Announces First Patient Dosed in Phase 2 Pivotal Study of IN10018 In Patients with Platinum-Resistant Recurrent Ovarian Cancer - PR Newswire

Nearly half (44%) of top 50 biopharma companies are now involved in RNA work sparking new demand for tools purpose built for the full spectrum of RNA R&D

SAN FRANCISCO, Sept. 7, 2022 /PRNewswire/ -- Benchling, the R&D Cloud powering the biotechnology industry, today launched the industry's first full set of capabilities for designing, modeling, and studying both natural and chemically modified RNA in a single solution. As the biopharmaceutical industry increases its focus on developing RNA therapeutics, Benchling's new RNA solution is the first purpose-built offering on the market to help R&D organizations accelerate the delivery of drug candidates. Featuring an RNA-aware registry with visualization tools for oligo and mRNA design and the only tool with support for chemical modification of mRNA sequences, RNA biologists and chemists can now collaborate more efficiently, standardize their work across teams, and develop drug candidates faster.

Following the successful deployment of RNA technology in the Pfizer-BioNTech and Moderna Covid-19 vaccines, biopharma companies have quickly shifted their pipelines to uncover therapeutic opportunities with RNA and mRNA. RNA therapeutics include a diverse group of therapeutic molecules that range from mRNA vaccines to antisense oligos, RNA-based gene therapy, and guide RNA-based CRISPR complexes. The unique function of these molecules, combined with the ability to adjust key properties through chemical modification or conjugation, has opened up novel ways of treating and preventing diseases. Nearly half (44%) of top 50 global biopharma companies are involved in RNA work through their own pipelines, M&A, or strategic alliances, based on GlobalData research1. Venture capital has also invested $3 billion into RNA-based therapies in 2020 alone, according to Nature.

While RNA therapeutics hold tremendous potential to impact human health, the R&D tools to create, test, and develop these molecules have been severely limited. Traditional chemistry tools cannot model the intricacies of RNA biology, while biology tools ignore the chemistry involved with RNA modifications altogether. As a result, there has not been a single software solution to date that addresses the combined biological and chemical nature of RNA therapeutics. Scientists have had to contend with manual, low-throughput, and disconnected software to manage their R&D work. Meanwhile, 82% of the pipeline of disclosed RNA and nucleotide therapeutics is in the research or preclinical stage of development2.

"We're at a tipping point for RNA therapeutics, having figured out tough challenges like durability and stability, the industry is now looking for the right tools to accelerate RNA R&D," said Ashu Singhal, co-founder and president of Benchling. "Covid vaccines were really just the beginning - as we put more tools in the hands of scientists to help support their RNA therapeutics R&D, this field will really take off. With Benchling's new RNA capabilities, scientists can now design, develop, and test a new mRNA vaccine or RNA cancer treatment from start to finish on a single platform."

"RNA has nearly unlimited potential to cure a wide range of diseases. Benchling's full set of purpose-built tools for RNA therapy development is going to enable us to realize this potential at an even greater pace than before," said Francois Vigneault, co-founder and CEO of Shape Therapeutics, an RNA technology company advancing programmable medicine and a longtime Benchling customer. "We are excited to see Benchling's continued investment in RNA innovation, and appreciate their commitment to helping companies like ShapeTX accelerate next-generation biopharma solutions."

Benchling's complete RNA solution is available today, and scientists working in RNA and mRNA therapeutics, RNA-based gene therapy, and gene editing will benefit from:

Along with the general availability launch of the RNA full solution, Benchling is making additional new product features generally available, including:

Benchling's mission is to unlock the power of biotechnology by creating modern software for modern science that empowers R&D teams to focus more time on science (not their software)! To learn more about Benchling and these new capabilities, please visit the company's What's New page.

About BenchlingBenchling is the pioneer of the R&D Cloud, software that unlocks the power of biotechnology. More than 200,000 scientists at over 1,000 companies and 7,500 academic and research institutions globally have adopted the Benchling R&D Cloud to make breakthrough discoveries and bring the next generation of medicines, food, and materials to market faster. The Benchling R&D Cloud helps these organizations modernize their scientific processes and accelerate collaboration so they can convert the complexity of biology into world-changing results. For more, please visit Benchling.comor follow us on Twitter at @Benchling.

1GlobalData by Benchling, August 20222GlobalData by Benchling, August 2022

Contact: [emailprotected]

SOURCE Benchling

See the original post here:
Benchling Launches the First Complete Solution for RNA R&D to Accelerate mRNA and RNA Therapeutics Development - PR Newswire